Pfizer: Patent Fears Priced In

My previous bullish thesis about Pfizer's stock (NYSE: PFE ) (NEOE: PFE:CA ) aged well as the stock delivered a 5% total return since early July. The stock outperformed the broader U.S. market over the same period. I am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and internationally.In recent years, ...